{"id":"https://openalex.org/W4387516581","doi":"https://doi.org/10.1038/s41408-023-00927-2","title":"Immune-depleted tumor microenvironment is associated with poor outcomes and BTK inhibitor resistance in mantle cell lymphoma","display_name":"Immune-depleted tumor microenvironment is associated with poor outcomes and BTK inhibitor resistance in mantle cell lymphoma","publication_year":2023,"publication_date":"2023-10-11","ids":{"openalex":"https://openalex.org/W4387516581","doi":"https://doi.org/10.1038/s41408-023-00927-2","pmid":"https://pubmed.ncbi.nlm.nih.gov/37821434","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/10567800"},"language":"en","primary_location":{"id":"doi:10.1038/s41408-023-00927-2","doi":"https://doi.org/10.1038/s41408-023-00927-2","is_oa":true,"landing_page_url":"https://doi.org/10.1038/s41408-023-00927-2","pdf_url":"https://www.nature.com/articles/s41408-023-00927-2.pdf","source":{"id":"https://openalex.org/S2496263508","display_name":"Blood Cancer Journal","issn_l":"2044-5385","issn":["2044-5385"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-1","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319965","host_organization_name":"Springer Nature","host_organization_lineage":["https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood Cancer Journal","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.nature.com/articles/s41408-023-00927-2.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5083223035","display_name":"Preetesh Jain","orcid":"https://orcid.org/0000-0003-2735-168X","observed_orcids":["https://orcid.org/0000-0003-2735-168X"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Preetesh Jain","raw_affiliation_strings":["Department of Lymphoma and Myeloma from The University of Texas MD Anderson Cancer Center, Houston, TX, USA. pjain@mdanderson.org","Department of Lymphoma and Myeloma from The University of Texas MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":"https://orcid.org/0000-0003-2735-168X","affiliations":[{"raw_affiliation_string":"Department of Lymphoma and Myeloma from The University of Texas MD Anderson Cancer Center, Houston, TX, USA. pjain@mdanderson.org","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"Department of Lymphoma and Myeloma from The University of Texas MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015633466","display_name":"Krystle J. Nomie","orcid":"https://orcid.org/0000-0002-3479-8247","observed_orcids":["https://orcid.org/0000-0002-3479-8247"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Krystle Nomie","raw_affiliation_strings":["BostonGene Corporation, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BostonGene Corporation, Boston, MA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090334093","display_name":"Nikita Kotlov","orcid":"https://orcid.org/0000-0002-6393-7357","observed_orcids":["https://orcid.org/0000-0002-6393-7357"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nikita Kotlov","raw_affiliation_strings":["BostonGene Corporation, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BostonGene Corporation, Boston, MA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5093040585","display_name":"VitaIy Segodin","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"VitaIy Segodin","raw_affiliation_strings":["BostonGene Corporation, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BostonGene Corporation, Boston, MA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085683341","display_name":"Holly Ann Hill","orcid":"https://orcid.org/0000-0003-3642-1897","observed_orcids":["https://orcid.org/0000-0003-3642-1897"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Holly Hill","raw_affiliation_strings":["Department of Lymphoma and Myeloma from The University of Texas MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma and Myeloma from The University of Texas MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053926894","display_name":"Chi Young Ok","orcid":"https://orcid.org/0000-0002-6822-7880","observed_orcids":["https://orcid.org/0000-0002-6822-7880"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Chi Young Ok","raw_affiliation_strings":["Department of Hematopathology at The University of Texas MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":"https://orcid.org/0000-0002-6822-7880","affiliations":[{"raw_affiliation_string":"Department of Hematopathology at The University of Texas MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061017702","display_name":"Ahmed Fetooh","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ahmed Fetooh","raw_affiliation_strings":["Department of Lymphoma and Myeloma from The University of Texas MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma and Myeloma from The University of Texas MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059373442","display_name":"Rashmi Kanagal\u2010Shamanna","orcid":"https://orcid.org/0000-0001-7829-5249","observed_orcids":["https://orcid.org/0000-0001-7829-5249"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rashmi Kanagal-Shamanna","raw_affiliation_strings":["Department of Hematopathology at The University of Texas MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":"https://orcid.org/0000-0001-7829-5249","affiliations":[{"raw_affiliation_string":"Department of Hematopathology at The University of Texas MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006947975","display_name":"Francisco Vega","orcid":"https://orcid.org/0000-0001-5956-452X","observed_orcids":["https://orcid.org/0000-0001-5956-452X"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Francisco Vega","raw_affiliation_strings":["Department of Hematopathology at The University of Texas MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematopathology at The University of Texas MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045749988","display_name":"Alexander Bagaev","orcid":"https://orcid.org/0000-0002-8680-854X","observed_orcids":["https://orcid.org/0000-0002-8680-854X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alexander Bagaev","raw_affiliation_strings":["BostonGene Corporation, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BostonGene Corporation, Boston, MA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044284041","display_name":"Nathan Hale Fowler","orcid":"https://orcid.org/0000-0002-9494-1877","observed_orcids":["https://orcid.org/0000-0002-9494-1877"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nathan Fowler","raw_affiliation_strings":["BostonGene Corporation, Boston, MA, USA","Department of Lymphoma and Myeloma from The University of Texas MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":"https://orcid.org/0000-0002-9494-1877","affiliations":[{"raw_affiliation_string":"BostonGene Corporation, Boston, MA, USA","institution_ids":[]},{"raw_affiliation_string":"Department of Lymphoma and Myeloma from The University of Texas MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082892912","display_name":"Christopher R. Flowers","orcid":"https://orcid.org/0000-0002-9524-3990","observed_orcids":["https://orcid.org/0000-0002-9524-3990"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christopher R. Flowers","raw_affiliation_strings":["Department of Lymphoma and Myeloma from The University of Texas MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma and Myeloma from The University of Texas MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5100438316","display_name":"Michael L. Wang","orcid":"https://orcid.org/0000-0001-9748-5486","observed_orcids":["https://orcid.org/0000-0001-9748-5486"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Michael Wang","raw_affiliation_strings":["Department of Lymphoma and Myeloma from The University of Texas MD Anderson Cancer Center, Houston, TX, USA. miwang@mdanderson.org","Department of Lymphoma and Myeloma from The University of Texas MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma and Myeloma from The University of Texas MD Anderson Cancer Center, Houston, TX, USA. miwang@mdanderson.org","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"Department of Lymphoma and Myeloma from The University of Texas MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5083223035","https://openalex.org/A5100438316"],"corresponding_institution_ids":["https://openalex.org/I1343551460"],"apc_list":{"value":4790,"currency":"USD","value_usd":4790},"apc_paid":{"value":4790,"currency":"USD","value_usd":4790},"fwci":3.3971,"has_fulltext":true,"cited_by_count":18,"citation_normalized_percentile":{"value":0.93108181,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":98,"max":99},"biblio":{"volume":"13","issue":"1","first_page":"156","last_page":"156"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0007999999797903001,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10685","display_name":"Viral-associated cancers and disorders","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mantle-cell-lymphoma","display_name":"mantle cell lymphoma","score":1.0},{"id":"https://openalex.org/keywords/tumor-microenvironment","display_name":"tumor microenvironment","score":0.9079999923706055},{"id":"https://openalex.org/keywords/ibrutinib-resistance","display_name":"ibrutinib resistance","score":0.8899999856948853},{"id":"https://openalex.org/keywords/bruton-tyrosine-kinase-inhibitors","display_name":"BTK inhibitors","score":0.9599999785423279},{"id":"https://openalex.org/keywords/t-cell-exhaustion","display_name":"T cell exhaustion","score":0.5389999747276306},{"id":"https://openalex.org/keywords/regulatory-t-cells","display_name":"regulatory T cells","score":0.9240000247955322},{"id":"https://openalex.org/keywords/tumor-immune-landscape","display_name":"tumor immune landscape","score":0.5989999771118164},{"id":"https://openalex.org/keywords/multi-omics-profiling","display_name":"multi-omics profiling","score":0.7789999842643738},{"id":"https://openalex.org/keywords/treatment-resistance","display_name":"treatment resistance","score":0.6240000128746033},{"id":"https://openalex.org/keywords/clinical-outcomes","display_name":"clinical outcomes","score":0.7049999833106995}],"concepts":[{"id":"https://openalex.org/C2777525834","wikidata":"https://www.wikidata.org/wiki/Q268713","display_name":"Mantle cell lymphoma","level":3,"score":0.810702919960022},{"id":"https://openalex.org/C90059517","wikidata":"https://www.wikidata.org/wiki/Q423572","display_name":"Bruton's tyrosine kinase","level":4,"score":0.7910645604133606},{"id":"https://openalex.org/C2779878957","wikidata":"https://www.wikidata.org/wiki/Q5984881","display_name":"Ibrutinib","level":4,"score":0.7830424904823303},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.6220701932907104},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.5898603200912476},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.5859021544456482},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5352663993835449},{"id":"https://openalex.org/C2776107976","wikidata":"https://www.wikidata.org/wiki/Q1786433","display_name":"Tumor microenvironment","level":3,"score":0.5098906755447388},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5032464861869812},{"id":"https://openalex.org/C194409129","wikidata":"https://www.wikidata.org/wiki/Q103824","display_name":"Hematology","level":2,"score":0.43047791719436646},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3043862581253052},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.18774211406707764},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.14340722560882568},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.07394653558731079},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011505","descriptor_name":"Protein-Tyrosine Kinases","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020522","descriptor_name":"Lymphoma, Mantle-Cell","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D059016","descriptor_name":"Tumor Microenvironment","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1038/s41408-023-00927-2","doi":"https://doi.org/10.1038/s41408-023-00927-2","is_oa":true,"landing_page_url":"https://doi.org/10.1038/s41408-023-00927-2","pdf_url":"https://www.nature.com/articles/s41408-023-00927-2.pdf","source":{"id":"https://openalex.org/S2496263508","display_name":"Blood Cancer Journal","issn_l":"2044-5385","issn":["2044-5385"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-1","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319965","host_organization_name":"Springer Nature","host_organization_lineage":["https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood Cancer Journal","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:10567800","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/10567800","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10567800/pdf/41408_2023_Article_927.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood Cancer J","raw_type":"Text"},{"id":"pmid:37821434","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/37821434","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood cancer journal","raw_type":"Letter"},{"id":"pmh:oai:doaj.org/article:19cd5314563442188352426c12d4f839","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/19cd5314563442188352426c12d4f839","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Blood Cancer Journal, Vol 13, Iss 1, Pp 1-5 (2023)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1038/s41408-023-00927-2","doi":"https://doi.org/10.1038/s41408-023-00927-2","is_oa":true,"landing_page_url":"https://doi.org/10.1038/s41408-023-00927-2","pdf_url":"https://www.nature.com/articles/s41408-023-00927-2.pdf","source":{"id":"https://openalex.org/S2496263508","display_name":"Blood Cancer Journal","issn_l":"2044-5385","issn":["2044-5385"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-1","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319965","host_organization_name":"Springer Nature","host_organization_lineage":["https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood Cancer Journal","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[{"id":"https://openalex.org/G5772955103","display_name":"NovaSeq6000","funder_award_id":"S10OD024977","funder_id":"https://openalex.org/F4320332161","funder_display_name":"National Institutes of Health"},{"id":"https://openalex.org/G9000878657","display_name":"Cancer Center Support Grant","funder_award_id":"P30CA016672","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320332521","display_name":"University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4387516581.pdf","grobid_xml":"https://content.openalex.org/works/W4387516581.grobid-xml"},"referenced_works_count":13,"referenced_works":["https://openalex.org/W2137228311","https://openalex.org/W2237195636","https://openalex.org/W2345102372","https://openalex.org/W2477374712","https://openalex.org/W2597269601","https://openalex.org/W2912552280","https://openalex.org/W2943984860","https://openalex.org/W2981435977","https://openalex.org/W3128501672","https://openalex.org/W3135611035","https://openalex.org/W3160458186","https://openalex.org/W3162215872","https://openalex.org/W3174387258"],"related_works":["https://openalex.org/W3213276390","https://openalex.org/W2983936248","https://openalex.org/W3029418215","https://openalex.org/W3183423524","https://openalex.org/W4405052816","https://openalex.org/W3217562101","https://openalex.org/W3095522695","https://openalex.org/W3160458186","https://openalex.org/W4318671905","https://openalex.org/W4294770998"],"abstract_inverted_index":{"Mantle":[0],"cell":[1,9,88,118,149],"lymphoma":[2,11],"(MCL)":[3],"is":[4,47],"a":[5,84,96,113,143],"generally":[6],"aggressive":[7],"B":[8],"non-Hodgkin":[10],"(B-NHL).":[12],"Outcomes":[13],"of":[14,21,52,98,116,131,188],"patients":[15,29,171,207],"have":[16,80],"improved":[17],"in":[18,45,60,86,146,169,192,203],"the":[19,132,167,178,186,189,201,210,222],"era":[20],"Bruton\u2019s":[22],"tyrosine":[23],"kinase":[24],"inhibitors":[25],"(BTKi).":[26],"However,":[27],"MCL":[28,46,148,170,206],"can":[30,38],"develop":[31],"resistance":[32,44,73,157],"to":[33,199,224],"BTKi":[34],"over":[35],"time":[36],"and":[37,55,136,139,155,180,208,215,221],"progress":[39],"[":[40,74,90,102,109,121,152,158,164],"1":[41],"].":[42,76,160],"Ibrutinib":[43],"correlated":[48],"with":[49,71,126],"an":[50],"overexpression":[51],"OXPHOS,":[53],"MYC":[54],"PI3K/AKT/m-TOR":[56],"pathways.":[57],"Somatic":[58],"mutations":[59],"TP53,":[61],"KMT2D,":[62],"NSD2,":[63],"SMARCA4,":[64],"CCND1,":[65],"TRAF2,":[66],"NFKBIE":[67],"genes":[68],"are":[69,124],"reported":[70],"ibrutinib":[72],"2":[75],"A":[77],"few":[78],"reports":[79],"also":[81],"demonstrated":[82],"that":[83],"decrease":[85],"T":[87,100,117],"numbers":[89],"3":[91],",":[92,104],"4":[93],"]":[94,111,123,154],"or":[95,112],"downregulation":[97],"effector/cytotoxic":[99],"cells":[101],"5":[103,122],"6":[105,159],"],":[106,166],"high":[107],"Tregs":[108],"7":[110],"decreased":[114],"expression":[115],"activation/co-stimulation":[119],"pathways":[120],"associated":[125],"resistant":[127],"MCL.":[128],"An":[129],"understanding":[130],"tumor":[133],"microenvironment":[134],"(TME)":[135],"its":[137],"cellular":[138],"analyte":[140],"composition":[141],"plays":[142],"critical":[144],"role":[145],"promoting":[147],"growth,":[150],"proliferation":[151],"8":[153],"treatment":[156],"Unlike":[161],"other":[162],"lymphomas":[163],"9":[165],"TME":[168,202,213],"has":[172],"not":[173],"been":[174],"fully":[175],"characterized":[176],"at":[177],"transcriptomic":[179],"genomic":[181],"levels.":[182],"To":[183],"further":[184],"understand":[185],"relevance":[187],"tumor-immune":[190],"landscape":[191],"tissue":[193],"microenvironments,":[194],"we":[195],"performed":[196],"multiomic":[197],"profiling":[198],"characterize":[200],"tissues":[204],"from":[205],"examined":[209],"relationship":[211],"between":[212],"subtypes":[214],"their":[216],"impact":[217],"on":[218],"clinical":[219],"outcome":[220],"response":[223],"BTKi.":[225]},"counts_by_year":[{"year":2026,"cited_by_count":5},{"year":2025,"cited_by_count":6},{"year":2024,"cited_by_count":7}],"updated_date":"2026-11-05T12:25:35.769452","created_date":"2023-10-12T00:00:00"}